22752
document
Simvastatin and preparation of polyunsaturated phospholipids produce similar changes in the phospholipid composition of high-density lipoproteins during hypercholesterolemia . We studied the phospholipid composition of high-density lipoproteins in patients with coronary heart disease and hypercholesterolemia treated with simvastatin ( Zocor , inhibitor of the key enzyme of cholesterol synthesis ) and preparation of polyunsaturated phospholipids ( lipostabil forte ) . Simvastatin produced a hypolipidemic effect and modulates the phospholipid composition of high-density lipoproteins ( similarly to lipostabil forte ) . These changes contribute to functional activity of high-density lipoproteins in the reverse cholesterol transport .
22753
Intervention_Pharmacological
Simvastatin
22754
Intervention_Pharmacological
polyunsaturated phospholipids
22755
Intervention_Pharmacological
simvastatin ( Zocor
22756
Intervention_Pharmacological
phospholipids ( lipostabil forte )
22757
Intervention_Pharmacological
Simvastatin
22758
Intervention_Pharmacological
lipostabil forte
22759
Outcome_Physical
hypolipidemic effect and modulates the phospholipid composition of high-density lipoproteins ( similarly to lipostabil forte ) .
22760
Outcome_Other
functional activity
22761
Outcome_Physical
high-density lipoproteins
22762
Participant_Condition
hypercholesterolemia
22763
Participant_Condition
coronary heart disease
22764
Participant_Condition
hypercholesterolemia
22765
Participant_Condition
simvastatin ( Zocor , inhibitor of the key enzyme of cholesterol synthesis )
22766
Participant_Condition
polyunsaturated phospholipids ( lipostabil forte )